We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Summary
Cases of medication errors have been identified internationally where tranexamic acid injection was inadvertently administered to the spinal cord (intrathecally or epidurally), resulting in severe pain, seizures, cardiac arrhythmias and deaths.
Injectable tranexamic acid should only be administered intravenously and must not be given intrathecally or epidurally.
Tranexamic acid is a clotting medicine that helps to control bleeding. Intravenous tranexamic acid is used during or after surgical procedures.
Most of the administration errors involved mix-ups of vials or ampoules resulting in administration of tranexamic acid instead of the intended injectable local anaesthetic (e.g., bupivacaine, levobupivacaine, prilocaine). At particular risk are procedures that may include intravenous injection of tranexamic acid along with intrathecally administered injectable products.
What health professionals should do
To minimise the risk, health professionals should consider taking preventative measures with both storage and administration of tranexamic acid.
It is highly recommended that syringes containing tranexamic acid be clearly labelled for intravenous use only. This will help to prevent any mix-ups during administration.
Additionally, it is advised that tranexamic acid injectables be stored separately from injectable local anaesthetics. This segregation will further reduce the risk of incorrect administration and enhance patient safety.
Health service managers should be alert to the Australian Commission on Safety and Quality’s National Standard for User-applied Labelling of Injectable Medicines, Fluids and Lines which is a mandatory requirement for meeting the National Safety and Quality Health Service Standards.
Background
The US Food and Drug Administration published an alert in October last year after strengthening warnings to the Prescribing Information (PI) over this issue.
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee reviewed cases in which tranexamic acid was given intrathecally or epidurally that resulted in severe pain, seizures, cardiac arrhythmias and deaths. Following this review, they issued a Dear Healthcare Professional letter to remind providers that tranexamic acid must not be administered intrathecally, epidurally, by intraventricular injection or by intracerebral application.
We reviewed the Australian PIs and found the wording was adequate and did not require updating, with the PIs stating that tranexamic acid is contraindicated for intrathecal or epidural use.
Disclaimer
Medicine Safety Updates are aimed at health professionals. They are intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicine Safety Updates is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2026
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.
For the latest safety information from us, subscribe to the TGA Safety Information email list via our website.
For correspondence or further information about Medicines Safety Update visit Contact us.
Medicines Safety Update is written by staff from the Pharmacovigilance Branch.